Terraflora Daily Care for gastrointestinal health

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a 12-week randomized, double-blind, placebo-controlled trial comparing Terraflora Daily Care, a synbiotic dietary supplement, to a placebo. Adults aged 25 and older with dysbiosis confirmed by a GA-Map stool test (score ≥3) will be enrolled at a single site in Richmond, Virginia. Participants who recently used probiotics or who have inflammatory bowel disease, other clinically significant chronic conditions, ongoing use of NSAIDs, PPIs, or antibiotics, or who are pregnant, breastfeeding, or daily smokers will be excluded. The study will track changes in objective markers of gastrointestinal function from stool testing and self-reported GI symptoms over the treatment period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adult males or females age ≥ 25 years
2. Ability to read and speak English
3. Dysbiosis (≥3 on GA-Map Dysbiosis Score) on a stool test (GI360 Profile, Doctor's Data, St. Charles, Illinois)

Exclusion Criteria:

1. Daily use within the past month of any probiotic or prebiotic supplement
2. Current diagnosis of inflammatory bowel disease, including Crohn's or ulcerative colitis
3. Current daily usage of non-steroidal anti-inflammatory drugs (NSAID), proton pump inhibitors (PPI), or antibiotic medications
4. Current daily tobacco smoker
5. Known allergies to any substance in the study products
6. Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks
7. Current diagnosis of any other chronic health condition (e.g., cancer, chronic kidney disease) deemed clinically contraindicated for the study protocol
8. Current participation in another clinical trial
9. Participants unable to provide consent

Where it's running

• OvationLab
  Richmond, Virginia, United States Recruiting

Study contacts

• Study coordinator: Chris D'Adamo, Ph.D.
• Email: chris@ovationlab.com
• Phone: 240-232-2103

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neonatal Echovirus 11 infections in Italy: virological, genomic and clinical insights

  This project will test whether sequencing virus samples from newborns with enterovirus infections, especially Echovirus 11, helps explain how the virus causes illness in the first weeks of life.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia, Lombardy · NCT07356583

• Frailty before GI cancer surgery: does frailty predict post-op outcomes in older adults?

  This study tests whether frailty measured before surgery can predict complications and recovery in patients 60 and older undergoing elective gastrointestinal cancer surgery.

  Recruiting Van Training and Research Hospital · Van, Van · NCT07815392

• Biological Collection to Help Create Models for Digestive Cancers and IBD

  Researchers are gathering tissue and biological samples from patients with inflammatory bowel disease or digestive cancers to build personalized models and test new therapies.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07782203

• Blood extracellular vesicles to detect chemotherapy-related nerve damage.

  We will test whether tiny blood particles called extracellular vesicles can predict who will develop chemotherapy-induced peripheral neuropathy in adults receiving taxane, platinum, or antimitotic chemotherapy.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07558447

• High-precision detection of leftover cancer using a liquid-biopsy platform (SHERLOCK)

  This project will test whether sensitive blood and other fluid tests for circulating tumor DNA can find leftover cancer (minimal residual disease) in adults treated with curative intent for breast, lung, melanoma, gynecologic, or genitourinary cancers.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07524114

• Dabrafenib and trametinib for rare cancers with BRAF V600 mutations

  This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.

  Recruiting at 15 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT07440290

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.